CN106620018A - Health-care product with anti-radiation effect and preparation method thereof - Google Patents
Health-care product with anti-radiation effect and preparation method thereof Download PDFInfo
- Publication number
- CN106620018A CN106620018A CN201611247287.3A CN201611247287A CN106620018A CN 106620018 A CN106620018 A CN 106620018A CN 201611247287 A CN201611247287 A CN 201611247287A CN 106620018 A CN106620018 A CN 106620018A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- care product
- hours
- health care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000003471 anti-radiation Effects 0.000 title claims abstract description 18
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 19
- 230000036541 health Effects 0.000 claims abstract description 18
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 17
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 17
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 17
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 17
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 17
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 17
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 17
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 17
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 17
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 17
- 239000000047 product Substances 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 240000000249 Morus alba Species 0.000 claims abstract description 15
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 14
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims abstract description 14
- 229960002216 methylparaben Drugs 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 13
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 13
- 239000006228 supernatant Substances 0.000 claims abstract description 13
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 12
- 240000001890 Ribes hudsonianum Species 0.000 claims abstract description 12
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims abstract description 12
- 235000001466 Ribes nigrum Nutrition 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 11
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 11
- 241001092459 Rubus Species 0.000 claims abstract description 11
- 235000015810 grayleaf red raspberry Nutrition 0.000 claims abstract description 11
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 10
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 10
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 9
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 9
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 9
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 9
- 241000132012 Atractylodes Species 0.000 claims abstract description 8
- 239000004744 fabric Substances 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 15
- 241001061264 Astragalus Species 0.000 claims description 10
- 235000006533 astragalus Nutrition 0.000 claims description 10
- 210000004233 talus Anatomy 0.000 claims description 10
- 241000092665 Atractylodes macrocephala Species 0.000 claims description 8
- 230000000249 desinfective effect Effects 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 244000241838 Lycium barbarum Species 0.000 claims description 4
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 4
- 235000015468 Lycium chinense Nutrition 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 abstract description 4
- -1 stir while adding Substances 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 description 15
- 241001092040 Crataegus Species 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 14
- 230000006378 damage Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000005778 DNA damage Effects 0.000 description 9
- 231100000277 DNA damage Toxicity 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 235000011034 Rubus glaucus Nutrition 0.000 description 8
- 235000009122 Rubus idaeus Nutrition 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 230000002633 protecting effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 241001165494 Rhodiola Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 244000111388 Rubus occidentalis Species 0.000 description 1
- 235000003942 Rubus occidentalis Nutrition 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000003927 comet assay Methods 0.000 description 1
- 231100000170 comet assay Toxicity 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000003904 radioactive pollution Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical group 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有抗辐射效果的保健品及其制备方法,其中保健品,由以下重量份的原料药配比而成,红树莓20~30份,黑莓15~25份,桑葚10~20份,枸杞子12~15份,黑加仑8~12份,鱼腥草7~15份、红景天5~10份、茯苓3~8份、陈皮5~10份、山楂6~10份、黄芪3~6份、川芎5~10份、白术3~8份。保健品的制备方法按照以下步骤进行:称取原材料加水浸泡后煎煮3次,分离出药液;将药液粗滤,并混合,冷却静置,取上清液;按照每1kg溶液加入5g尼泊金甲酯的比例加入尼泊金甲酯粉末,边加边搅拌,充分混匀,静置后,用滤布过滤;将制得的滤液灭菌、消毒、封装,制成口服液制剂。
The invention discloses a health care product with anti-radiation effect and a preparation method thereof, wherein the health care product is prepared from the following ingredients by weight: 20-30 parts of red raspberry, 15-25 parts of blackberry, and 10 parts of mulberry ~20 parts, 12~15 parts of medlar, 8~12 parts of black currant, 7~15 parts of Houttuynia cordata, 5~10 parts of Rhodiola rosea, 3~8 parts of poria cocos, 5~10 parts of tangerine peel, 6~10 parts of hawthorn 3-6 parts of Radix Astragali, 5-10 parts of Rhizoma Chuanxiong, and 3-8 parts of Atractylodes Rhizoma. The preparation method of the health care product is carried out according to the following steps: Weigh the raw materials, soak them in water, and decoct 3 times to separate the medicinal liquid; coarsely filter the medicinal liquid, mix them, cool and stand still, and take the supernatant; add 5g of Add methylparaben powder according to the ratio of methylparaben, stir while adding, mix well, after standing still, filter with filter cloth; sterilize, disinfect and package the obtained filtrate to make oral liquid preparation .
Description
技术领域technical field
本发明属于食药保健品技术领域,涉及一种具有抗辐射效果的保健品及其制备方法。The invention belongs to the technical field of food, medicine and health products, and relates to a health product with anti-radiation effect and a preparation method thereof.
背景技术Background technique
放射性物质广泛应用于科技、生产和日常生活,不可避免地会给人们的生活环境及人体造成放射性污染及放射危害,其中对于人体危害的严重性亦为人们所日益关注。迄今为止,恶性肿瘤患者临床治疗时,约70%以上的癌症患者离不开放射治疗,放疗后患者体内产生大量的活性氧,过量的活性氧引起的脂质过氧化,破坏膜的结构、损伤蛋白质和核酸,对人体健康造成严重影响。既然人们己经无法避免辐射,那么如何防患于未然,如何减少辐射给人类带来的损伤则引起了普遍关注。Radioactive substances are widely used in science and technology, production and daily life, which will inevitably cause radioactive pollution and radiation hazards to people's living environment and human body, and the seriousness of the harm to human body has also attracted increasing attention. So far, in the clinical treatment of malignant tumor patients, more than 70% of cancer patients cannot do without radiotherapy. After radiotherapy, a large amount of active oxygen is produced in the patient's body, and lipid peroxidation caused by excessive active oxygen destroys the structure of the membrane and damages Proteins and nucleic acids have a serious impact on human health. Now that people cannot avoid radiation, how to prevent problems before they happen and how to reduce the damage caused by radiation to human beings has attracted widespread attention.
目前对辐射损伤的防护除物理措施外,主要侧重于药物防护,由于药物或多或少都存在一定不良反应,加之费用因素,使药物在辐射防护中难以作为常规制剂应用。自古东方亚洲国家就有药食同源的传统,非常注重保健食品、功能食品的开发,而功能性食品添加剂,特别是一些天然提取物的明显功效,也早己在国际上得到认可。In addition to physical measures, the current protection against radiation damage mainly focuses on drug protection. Due to the adverse reactions of drugs more or less, coupled with cost factors, it is difficult for drugs to be used as conventional preparations in radiation protection. Since ancient times, Eastern Asian countries have had a tradition of homology of medicine and food, and they have paid great attention to the development of health food and functional food. Functional food additives, especially the obvious efficacy of some natural extracts, have long been recognized internationally.
发明内容Contents of the invention
为实现上述目的,本发明提供一种具有抗辐射效果的保健品及其制备方法,解决了现有技术中存在的放射性治疗的辐射对人体造成机体损伤的问题。In order to achieve the above purpose, the present invention provides a health care product with anti-radiation effect and its preparation method, which solves the problem in the prior art that the radiation of radiotherapy causes damage to the human body.
本发明所采用的技术方案是,一种具有抗辐射效果的保健品,由以下重量份的原料药配比而成,红树莓20~30份,黑莓15~25份,桑葚10~20份,枸杞子12~15份,黑加仑8~12份,鱼腥草7~15份、红景天5~10份、茯苓3~8份、陈皮5~10份、山楂6~10份、黄芪3~6份、川芎5~10份、白术3~8份。The technical solution adopted in the present invention is, a health care product with anti-radiation effect, which is formed by the following raw materials in parts by weight: 20-30 parts of red raspberry, 15-25 parts of blackberry, and 10-20 parts of mulberry , 12-15 parts of medlar, 8-12 parts of black currant, 7-15 parts of Houttuynia cordata, 5-10 parts of rhodiola rosea, 3-8 parts of Poria cocos, 5-10 parts of tangerine peel, 6-10 parts of hawthorn, 6-10 parts of astragalus 3-6 parts, Chuanxiong 5-10 parts, Atractylodes macrocephala 3-8 parts.
本发明采用的另一技术方案是,该具有抗辐射效果的保健品的制备方法,具体按照以下步骤进行:Another technical solution adopted by the present invention is that the preparation method of the health product with anti-radiation effect is specifically carried out according to the following steps:
步骤1,称取红树莓20~30份,黑莓15~25份,桑葚10~20份,枸杞子12~15份,黑加仑8~12份,鱼腥草7~15份、红景天5~10份、茯苓3~8份、陈皮5~10份、山楂6~10份、黄芪3~6份、川芎5~10份、白术3~8份,加8~15倍的水浸泡后煎煮3次,分离出药液;Step 1, weigh 20-30 parts of red raspberry, 15-25 parts of blackberry, 10-20 parts of mulberry, 12-15 parts of medlar, 8-12 parts of black currant, 7-15 parts of Houttuynia cordata, Rhodiola rosea 5-10 parts, 3-8 parts of Poria cocos, 5-10 parts of tangerine peel, 6-10 parts of hawthorn, 3-6 parts of astragalus, 5-10 parts of Chuanxiong, 3-8 parts of Atractylodes macrocephala, add 8-15 times of water to soak Decoct 3 times, separate the liquid medicine;
步骤2,将步骤1中3次煎煮后的药液粗滤,并将滤液混合,冷却静置2~4小时,取上清液;Step 2, coarsely filter the medicinal liquid decocted for 3 times in step 1, mix the filtrate, cool and stand for 2 to 4 hours, and take the supernatant;
步骤3,取步骤2制得的上清液,按照每1kg溶液加入5g尼泊金甲酯的比例加入尼泊金甲酯粉末,边加边搅拌,充分混匀,静置3~6小时后,用滤布过滤;Step 3, take the supernatant obtained in step 2, add methylparaben powder according to the ratio of 5g methylparaben per 1kg solution, stir while adding, mix well, and let it stand for 3 to 6 hours , filter with filter cloth;
步骤4,将步骤3制得的滤液灭菌、消毒、封装,制成口服液制剂。Step 4, sterilizing, disinfecting and packaging the filtrate obtained in step 3 to make an oral liquid preparation.
上述步骤1中,加水浸泡3~6小时;每次煎煮1.5~2.5小时。In the above step 1, soak in water for 3 to 6 hours; decoct for 1.5 to 2.5 hours each time.
上述步骤2中,滤液冷却至15℃~25℃。In the above step 2, the filtrate is cooled to 15°C to 25°C.
本发明的有益效果是,本发明药物具有提高机体免疫功能、能清除体内自由基,保护造血功能,适用于预防和治疗辐射引起的机体损伤。The beneficial effect of the invention is that the medicine of the invention can improve the immune function of the body, can remove free radicals in the body, protect the hematopoietic function, and is suitable for preventing and treating body damage caused by radiation.
附图说明Description of drawings
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings that need to be used in the description of the embodiments or the prior art. Obviously, the accompanying drawings in the following description are only These are some embodiments of the present invention. Those skilled in the art can also obtain other drawings based on these drawings without creative work.
图1是本发明一种具有抗辐射效果的保健品及其制备方法药效试验中各组大鼠淋巴细胞DNA损伤情况图;Fig. 1 is a kind of health product with anti-radiation effect of the present invention and preparation method drug effect test in each group's lymphocyte DNA damage situation figure of rat;
图2是本发明一种具有抗辐射效果的保健品及其制备方法药效试验中复方树莓籽粉对大鼠淋巴细胞DNA的影响图。Fig. 2 is a diagram of the influence of compound raspberry seed powder on rat lymphocyte DNA in a health product with anti-radiation effect and its preparation method in the efficacy test of the present invention.
其中,图2A.空白对照组,图2B.单纯辐射组,图2C.维生素联合应用组,图2D.复方树莓籽粉组。Among them, Fig. 2A. Blank control group, Fig. 2B. Simple radiation group, Fig. 2C. Vitamin combined application group, Fig. 2D. Compound raspberry seed powder group.
具体实施方式detailed description
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some, not all, embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.
本发明一种具有抗辐射效果的保健品,由以下重量份的原料药配比而成,红树莓20~30份,黑莓15~25份,桑葚10~20份,枸杞子12~15份,黑加仑8~12份,鱼腥草7~15份、红景天5~10份、茯苓3~8份、陈皮5~10份、山楂6~10份、黄芪3~6份、川芎5~10份、白术3~8份。The health care product with anti-radiation effect of the present invention is prepared from the following raw materials by weight: 20-30 parts of red raspberry, 15-25 parts of blackberry, 10-20 parts of mulberry, and 12-15 parts of medlar , 8-12 parts of black currant, 7-15 parts of Houttuynia cordata, 5-10 parts of rhodiola rosea, 3-8 parts of poria cocos, 5-10 parts of tangerine peel, 6-10 parts of hawthorn, 3-6 parts of astragalus, 5 parts of chuanxiong ~10 parts, 3~8 parts of Atractylodes macrocephala.
本发明中各原材料的药理作用如下:The pharmacological action of each raw material among the present invention is as follows:
红树莓:含有丰富的维生素A、维生素C、钙、钾、镁等营养元素以及大量纤维,能有效缓解心绞痛等心血管疾病,含有丰富的水杨酸、酚酸等物质,能有效地保护心脏,预防高血压、血管壁粥样硬化、心脑血管脆化破裂等心脑血管疾病。Red raspberry: rich in vitamin A, vitamin C, calcium, potassium, magnesium and other nutrients as well as a lot of fiber, which can effectively relieve angina pectoris and other cardiovascular diseases, rich in salicylic acid, phenolic acid and other substances, can effectively protect Heart, prevent cardiovascular and cerebrovascular diseases such as high blood pressure, atherosclerosis of blood vessel wall, embrittlement and rupture of cardiovascular and cerebrovascular vessels.
黑莓:维生素C含量丰富,特别是所含鞣化酸被证实是预防癌症最有效的物质,黑树莓籽具有增强免疫、促进造血红细胞生长、防止人体动脉及骨胳关节硬化、促进新陈代谢等功能。Blackberry: Rich in vitamin C, especially the tanned acid contained in it has been proven to be the most effective substance for preventing cancer. Black raspberry seeds have the functions of enhancing immunity, promoting the growth of hematopoietic red blood cells, preventing hardening of human arteries and bones and joints, and promoting metabolism. .
桑葚:含有的脂肪酸具有分解脂肪,降低血脂,防止血管硬化等作用,桑椹籽含有的乌发素能使头发变的黑而亮泽。桑椹籽有改善皮肤,包括头皮血液供应,营养肌肤,使皮肤白嫩及乌发等作用,并能延缓衰老。桑椹籽具有免疫促进作用,可以防癌抗癌。桑椹籽可以明目,缓解眼睛疲劳干涩的症状,尤其适合肝肾阴血不足者,少年发白者,病后体虚、体弱、习惯性便秘者。Mulberry: The fatty acid contained in it can decompose fat, reduce blood fat, and prevent vascular sclerosis, etc. The black hair contained in mulberry seed can make hair black and shiny. Mulberry seeds can improve the skin, including the blood supply of the scalp, nourish the skin, make the skin white and tender, black hair, etc., and can delay aging. Mulberry seeds have immune-boosting effects and can prevent and fight cancer. Mulberry seeds can improve eyesight and relieve eye fatigue and dryness. It is especially suitable for those with deficiency of Yin and blood in the liver and kidney, those with gray hair in teenagers, and those who are physically weak, weak, and habitually constipated after illness.
枸杞子:含有甜菜碱、阿托品、天仙子胺。具有促进免疫,抗衰老,抗肿瘤,清除自由基,抗疲劳,抗辐射,保肝,对生殖功能保护和改善等作用。甜菜碱对脂质具有代谢或抗脂肪肝的作用。枸杞所含有的类胡萝卜素则具有非常重要的药用价值。很多研究已经证明枸杞具有提高人体免疫功能,预防和抑制肿瘤及预防动脉粥样硬化等作用。Lycium barbarum: Contains betaine, atropine, and hyoscyamine. It has the effects of promoting immunity, anti-aging, anti-tumor, scavenging free radicals, anti-fatigue, anti-radiation, protecting liver, protecting and improving reproductive functions, etc. Betaine has a metabolic or anti-fatty liver effect on lipids. The carotenoids contained in wolfberry have very important medicinal value. Many studies have proved that wolfberry has the functions of improving human immune function, preventing and inhibiting tumors and preventing atherosclerosis.
黑加仑:含有非常丰富的维生素C、磷、镁、钾、钙、花青素、酚类物质。具有多种养生功效,如坚固牙龈、保护肝脏、改善视功能,抗衰老,补血补气,尤其黑加仑籽中的多不饱和脂肪酸还具有良好的保护心脑血管的作用。Black currant: It is very rich in vitamin C, phosphorus, magnesium, potassium, calcium, anthocyanins, and phenolic substances. It has a variety of health-preserving effects, such as strengthening the gums, protecting the liver, improving visual function, anti-aging, nourishing blood and qi, especially the polyunsaturated fatty acids in black currant seeds also have a good effect on protecting the cardiovascular and cerebrovascular.
鱼腥草:所含鱼腥草素、月桂醛、甲基正壬基酮、香乙烯及槲皮甙、蕺菜碱等挥发油成分,对金黄色葡萄球菌、白色葡萄球菌、痢疾杆菌、绿脓杆菌、变形杆菌、副大肠杆菌、革兰阳性芽孢杆菌等均有一定抑制作用,对金黄色葡萄球菌和白色葡萄球菌作用较强。新鱼腥草素能促进组织再生,对艾氏腹水癌具有抑制效果。Houttuynia cordata: It contains volatile oil components such as houttuyniatin, lauric aldehyde, methyl n-nonyl ketone, balsamic vinyl, quercetin, and adenine, which are effective against Staphylococcus aureus, Staphylococcus albus, Shigella, Pseudomonas Bacillus, Proteus, Escherichia coli, Gram-positive bacillus, etc. all have certain inhibitory effects, and have stronger effects on Staphylococcus aureus and Staphylococcus albus. Neohouttuyfotin can promote tissue regeneration and has inhibitory effect on Ehrlich ascites carcinoma.
红景天:一些报告指出红景天具有抗癌及抗突变的能力,它的抗癌机理在于细胞生长周期控制并使细胞凋亡。2006年一项研究指出红景天能抑制HL-60血癌细胞的分裂过程及减低它们的生存机会。另外,红景天可直接抑制肺癌细胞的生长及扩散。Rhodiola: Some reports point out that Rhodiola has anti-cancer and anti-mutation capabilities. Its anti-cancer mechanism lies in the control of cell growth cycle and apoptosis. A 2006 study pointed out that Rhodiola can inhibit the division process of HL-60 blood cancer cells and reduce their chances of survival. In addition, Rhodiola can directly inhibit the growth and spread of lung cancer cells.
茯苓:茯苓聚糖本身无抗肿瘤作用,但茯苓多糖(即茯苓次聚糖)、羧甲基茯苓多糖对小鼠肉瘤S180实体型及腹水转实体型、子宫颈癌S14实体型及腹水转实体型等均有不同程度的抑瘤作用。羧甲基茯苓多糖对小鼠移植肿瘤U14有较强的抑制作用;对艾氏腹水癌亦有一定抑制作用。试验表明,羧甲基茯苓多糖对艾氏腹水癌细胞的DNA合成有抑制作用。茯苓次聚糖对小鼠肉瘤S180有抑制作用,抑制率达96.88%。茯苓多糖F1和H11,具明显抗肿瘤活性。Poria cocos: Poria cocos polysaccharide itself has no anti-tumor effect, but pachycos polysaccharide (ie pachyphyllin) and carboxymethyl pachymane polysaccharide have effects on mouse sarcoma S180 solid type and ascites-transformed solid type, cervical cancer S14 solid-type and ascites-transformed solid type. Types and so on have different degrees of anti-tumor effect. Carboxymethylpachysan has a strong inhibitory effect on transplanted tumor U14 in mice; it also has a certain inhibitory effect on Ehrlich ascites carcinoma. Experiments have shown that carboxymethyl pachymane can inhibit the DNA synthesis of Ehrlich ascites cancer cells. Poria cocos polysaccharide has inhibitory effect on mouse sarcoma S180, and the inhibition rate reaches 96.88%. Poria polysaccharides F1 and H11 have obvious antitumor activity.
陈皮:醇提物等能兴奋心肌,它还可使血管产生轻度的收缩,迅速升高血压。陈皮中的果胶对高脂饮食引起的动脉硬化也有一定的预防作用。Tangerine peel: Alcohol extracts can excite the myocardium, and it can also cause mild contraction of blood vessels and rapidly increase blood pressure. The pectin in tangerine peel also has a certain preventive effect on arteriosclerosis caused by high-fat diet.
山楂:山楂的主要成分是黄酮类物质,对心血管系统有明显的药理作用。目前,从山楂中分离的黄酮成分有30余种,主要有含碳键的黄酮苷类、黄酮醇及其苷类、双氧黄酮苷类、聚合黄酮类。另一类较为重要的成分是三萜类物质,有强心、增加冠脉血流、改善血流循环等重要作用。此外,山楂中含有机酸如氯原酸、咖啡酸及鞣质、鞣酐、表儿茶酚、胆碱、乙酰胆碱、β谷甾醇、胡萝卜素及大量Vit C等。山楂中含有的牡荆素等化合物具有抗癌作用,常用山楂有利于防癌。实验表明,山楂片水煎液可延长长瘤动物的寿命,如可抑制小鼠艾氏腹水癌细胞作用,对人的子宫颈癌TCC-26抑制率达70%。Hawthorn: The main component of hawthorn is flavonoids, which have obvious pharmacological effects on the cardiovascular system. At present, there are more than 30 kinds of flavonoids isolated from hawthorn, mainly including flavonoid glycosides containing carbon bonds, flavonols and their glycosides, dioxyflavone glycosides, and polymerized flavonoids. Another important component is triterpenes, which have important functions such as strengthening the heart, increasing coronary blood flow, and improving blood circulation. In addition, hawthorn contains organic acids such as chlorogenic acid, caffeic acid and tannins, tannins, epicatechin, choline, acetylcholine, β-sitosterol, carotene and a large amount of Vit C, etc. Compounds such as vitexin contained in hawthorn have anti-cancer effects, and commonly used hawthorn is beneficial to cancer prevention. Experiments have shown that the water decoction of hawthorn slices can prolong the lifespan of animals with tumors, for example, it can inhibit the effect of Ehrlich ascites cancer cells in mice, and the inhibition rate of human cervical cancer TCC-26 can reach 70%.
黄芪:能显著增加血液中的白细胞总数,促进中性粒细胞及巨噬细胞的吞噬功能和杀菌能力。黄芪能明显增强细胞免疫,促进PHA、COnA、PWM(美洲商陆)引起的淋巴细胞转化。黄芪多糖能升高正常大鼠红细胞的比容,增加红细胞数。黄芪还能防治因辐射而造成的小鼠外周血白细胞总数、骨髓有核细胞数的减少,可促进造血干细胞的分化和增殖。Astragalus: It can significantly increase the total number of white blood cells in the blood, and promote the phagocytosis and bactericidal ability of neutrophils and macrophages. Astragalus can significantly enhance cellular immunity and promote lymphocyte transformation caused by PHA, COnA, and PWM (Pokeweed). Astragalus polysaccharides can increase the specific volume of red blood cells in normal rats and increase the number of red blood cells. Astragalus can also prevent the reduction of the total number of peripheral blood leukocytes and bone marrow nucleated cells in mice caused by radiation, and can promote the differentiation and proliferation of hematopoietic stem cells.
川芎:川芎对大肠、痢疾(宋内氏)、变形、绿脓、伤寒、副伤寒杆菌及霍乱弧菌等有抑制作用。川芎水浸剂(1:3)在试管内对某些致病性皮肤真菌也有抑制作用。川芎水溶性粗制剂对大鼠、小鼠及犬的放射线照射与氮芥损伤均有保护作用。川芎对大鼠的抗射效果比小鼠好,ip比im给药效果好,im给药较ig效果好。Chuanxiong: Chuanxiong has inhibitory effects on large intestine, dysentery (Sonnei), deformation, pus aeruginosa, typhoid fever, paratyphoid bacillus and Vibrio cholerae. Chuanxiong water extract (1:3) also has inhibitory effect on some pathogenic skin fungi in test tube. The water-soluble crude preparation of Chuanxiong Rhizoma Rhizoma Chuanxiong has protective effect on radiation exposure and nitrogen mustard injury in rats, mice and dogs. The anti-radiation effect of Rhizoma Chuanxiong on rats is better than that on mice, the effect of ip administration is better than that of im administration, and the effect of im administration is better than that of ig.
白术:有血管扩张作用。对心脏呈抑制作用,白术挥发油中之中性油对食管癌细胞有明显抑制作用。10mcg/ml时,于24小时内可使癌细胞全部脱落。5mcg/ml时,可使大部分癌细胞脱落,残存的小片细胞或散在细胞呈核固缩,核仁模糊不清,泡质多空泡。白术挥发油50-100mg/kg腹腔注射对艾氏腹水癌有显著抑制作用。全身给药时,对实质性实体癌的疗效则报道不一致。对358种植物药、中药单方和复方进行筛选时,白术挥发油对小鼠肉瘤-180的抑制作用最强(抑制率为31-49%)另有报道对S-180,S-37,U-14和W-256,以及白血病模型(L615均无明显作用。近报道,白术对methA肿瘤的中如活性比对照组明显增加,并显著增强MethA肿瘤的迟发性超敏反应,还促进植物血细胞凝集素-P和脂多糖诱导的幼若化反应。Atractylodes macrocephala: It has the effect of dilating blood vessels. It has an inhibitory effect on the heart, and the neutral oil in the volatile oil of Atractylodes Rhizoma Atractylodes Rhizome has obvious inhibitory effect on esophageal cancer cells. At 10mcg/ml, all cancer cells can be shed within 24 hours. At 5mcg/ml, most of the cancer cells can fall off, and the remaining small pieces of cells or scattered cells show nuclear pyknosis, blurred nucleoli, and many vacuoles in the vesicles. Atractylodes volatile oil 50-100mg/kg intraperitoneal injection has a significant inhibitory effect on Ehrlich ascites carcinoma. When administered systemically, efficacy against solid solid cancers has been inconsistently reported. When screening 358 kinds of herbal medicines, traditional Chinese medicine single prescriptions and compound prescriptions, Atractylodes macrocephala volatile oil has the strongest inhibitory effect on mouse sarcoma-180 (inhibition rate is 31-49%). Another report has S-180, S-37, U- 14 and W-256, as well as the leukemia model (L615) had no significant effect. Recently, it was reported that the neutralization activity of Atractylodes macrocephala on methA tumors was significantly higher than that of the control group, and significantly enhanced the delayed hypersensitivity of MethA tumors, and also promoted plant hemocytes Lectin-P and lipopolysaccharide-induced juvenile response.
本发明具有抗辐射效果的保健品的制备方法,具体按照以下步骤进行:The preparation method of the health product with anti-radiation effect of the present invention is specifically carried out according to the following steps:
步骤1,称取红树莓20~30份,黑莓15~25份,桑葚10~20份,枸杞子12~15份,黑加仑8~12份,鱼腥草7~15份、红景天5~10份、茯苓3~8份、陈皮5~10份、山楂6~10份、黄芪3~6份、川芎5~10份、白术3~8份,加8~15倍的水浸泡后煎煮3次,分离出药液;Step 1, weigh 20-30 parts of red raspberry, 15-25 parts of blackberry, 10-20 parts of mulberry, 12-15 parts of medlar, 8-12 parts of black currant, 7-15 parts of Houttuynia cordata, Rhodiola rosea 5-10 parts, 3-8 parts of Poria cocos, 5-10 parts of tangerine peel, 6-10 parts of hawthorn, 3-6 parts of astragalus, 5-10 parts of Chuanxiong, 3-8 parts of Atractylodes macrocephala, add 8-15 times of water to soak Decoct 3 times, separate the liquid medicine;
步骤2,将步骤1中3次煎煮后的药液粗滤,并将滤液混合,冷却静置2~4小时,取上清液;Step 2, coarsely filter the medicinal liquid decocted for 3 times in step 1, mix the filtrate, cool and stand for 2 to 4 hours, and take the supernatant;
步骤3,取步骤2制得的上清液,按照每1kg溶液加入5g尼泊金甲酯的比例加入尼泊金甲酯粉末,边加边搅拌,充分混匀,静置3~6小时后,用滤布过滤;Step 3, take the supernatant obtained in step 2, add methylparaben powder according to the ratio of 5g methylparaben per 1kg solution, stir while adding, mix well, and let it stand for 3 to 6 hours , filter with filter cloth;
步骤4,将步骤3制得的滤液灭菌、消毒、封装,制成口服液制剂。Step 4, sterilizing, disinfecting and packaging the filtrate obtained in step 3 to make an oral liquid preparation.
上述步骤1中,加水浸泡3~6小时;每次煎煮1.5~2.5小时。In the above step 1, soak in water for 3 to 6 hours; decoct for 1.5 to 2.5 hours each time.
上述步骤2中,滤液冷却至15℃~25℃。In the above step 2, the filtrate is cooled to 15°C-25°C.
实施例1Example 1
步骤1,称取红树莓25份,黑莓20份,桑葚15份,枸杞子13份,黑加仑10份,鱼腥草11份、红景天5份、茯苓5份、陈皮8份、山楂8份、黄芪4份、川芎7份、白术5份,加10倍的水浸泡4.5小时后煎煮3次,每次煎煮2小时,分离出药液;Step 1. Weigh 25 parts of red raspberry, 20 parts of blackberry, 15 parts of mulberry, 13 parts of medlar, 10 parts of black currant, 11 parts of Houttuynia cordata, 5 parts of rhodiola rosea, 5 parts of poria cocos, 8 parts of tangerine peel, hawthorn 8 parts, 4 parts of Radix Astragali, 7 parts of Rhizoma Chuanxiong, 5 parts of Atractylodes Rhizome, add 10 times of water to soak for 4.5 hours, then decoct 3 times, each time for 2 hours, separate the liquid medicine;
步骤2,将步骤1中3次煎煮后的药液粗滤,并将滤液混合,冷却至20℃静置3小时,取上清液;Step 2, coarsely filter the medicinal liquid decocted for 3 times in step 1, mix the filtrate, cool to 20°C and let it stand for 3 hours, and take the supernatant;
步骤3,取步骤2制得的上清液,按照每1kg溶液加入5g尼泊金甲酯的比例加入尼泊金甲酯粉末,边加边搅拌,充分混匀,静置5小时后,用滤布过滤;Step 3, take the supernatant obtained in step 2, add methylparaben powder according to the ratio of adding 5g methylparaben per 1kg solution, stir while adding, fully mix, after standing for 5 hours, use filter cloth filter;
步骤4,将步骤3制得的滤液灭菌、消毒、封装,制成口服液制剂。Step 4, sterilizing, disinfecting and packaging the filtrate obtained in step 3 to make an oral liquid preparation.
实施例2Example 2
步骤1,称取红树莓20份,黑莓15份,桑葚10份,枸杞子12份,黑加仑8份,鱼腥草7份、红景天5份、茯苓3份、陈皮5份、山楂6份、黄芪3份、川芎5份、白术3份,加8倍的水浸泡3小时后煎煮3次,每次煎煮1.5小时,分离出药液;Step 1. Weigh 20 parts of red raspberry, 15 parts of blackberry, 10 parts of mulberry, 12 parts of medlar, 8 parts of black currant, 7 parts of Houttuynia cordata, 5 parts of Rhodiola rosea, 3 parts of poria cocos, 5 parts of tangerine peel, hawthorn 6 parts, 3 parts of Radix Astragali, 5 parts of Rhizoma Chuanxiong, 3 parts of Atractylodes Rhizome, add 8 times the amount of water to soak for 3 hours, then decoct 3 times, each time for 1.5 hours, separate the liquid medicine;
步骤2,将步骤1中3次煎煮后的药液粗滤,并将滤液混合,冷却至15℃静置2小时,取上清液;Step 2, coarsely filter the medicinal liquid decocted for 3 times in step 1, mix the filtrate, cool to 15°C and let it stand for 2 hours, and take the supernatant;
步骤3,取步骤2制得的上清液,按照每1kg溶液加入5g尼泊金甲酯的比例加入尼泊金甲酯粉末,边加边搅拌,充分混匀,静置3小时后,用滤布过滤;Step 3, take the supernatant obtained in step 2, add methylparaben powder according to the ratio of adding 5g methylparaben per 1kg solution, stir while adding, fully mix, after standing for 3 hours, use filter cloth filter;
步骤4,将步骤3制得的滤液灭菌、消毒、封装,制成口服液制剂。Step 4, sterilizing, disinfecting and packaging the filtrate obtained in step 3 to make an oral liquid preparation.
实施例3Example 3
步骤1,称取红树莓30份,黑莓25份,桑葚20份,枸杞子15份,黑加仑12份,鱼腥草15份、红景天10份、茯苓8份、陈皮10份、山楂10份、黄芪6份、川芎10份、白术8份,加15倍的水浸泡6小时后煎煮3次,每次煎煮205小时,分离出药液;Step 1. Weigh 30 parts of red raspberry, 25 parts of blackberry, 20 parts of mulberry, 15 parts of medlar, 12 parts of black currant, 15 parts of Houttuynia cordata, 10 parts of Rhodiola rosea, 8 parts of poria cocos, 10 parts of tangerine peel, hawthorn 10 parts, 6 parts of Radix Astragali, 10 parts of Rhizoma Chuanxiong, 8 parts of Atractylodes Rhizome, add 15 times the amount of water to soak for 6 hours, then decoct 3 times, decoct for 205 hours each time, and separate the liquid medicine;
步骤2,将步骤1中3次煎煮后的药液粗滤,并将滤液混合,冷却至25℃静置4小时,取上清液;Step 2, coarsely filter the medicinal liquid decocted for 3 times in step 1, mix the filtrate, cool to 25°C and let it stand for 4 hours, and take the supernatant;
步骤3,取步骤2制得的上清液,按照每1kg溶液加入5g尼泊金甲酯的比例加入尼泊金甲酯粉末,边加边搅拌,充分混匀,静置6小时后,用滤布过滤;Step 3, take the supernatant obtained in step 2, add methylparaben powder according to the ratio of adding 5g methylparaben per 1kg solution, stir while adding, fully mix, after standing for 6 hours, use filter cloth filter;
步骤4,将步骤3制得的滤液灭菌、消毒、封装,制成口服液制剂。Step 4, sterilizing, disinfecting and packaging the filtrate obtained in step 3 to make an oral liquid preparation.
本发明一种具有抗辐射效果的保健品的药效学试验和结果如下:A kind of pharmacodynamics test and the result of the health product with anti-radiation effect of the present invention are as follows:
步骤1,动物处理:实验动物适应性喂养一周后,A、B组不做任何处理,C组维生素E(30mg/kg)和维生素C(50mg/kg)混合灌胃,D组复方树莓籽粉(1.25g/kg)灌胃,C、D组药物皆用生理盐水溶解至2ml,连续灌胃7d,自由饮水和进食;Step 1, animal treatment: After the experimental animals were fed adaptively for one week, groups A and B were not given any treatment, group C was given a mixture of vitamin E (30mg/kg) and vitamin C (50mg/kg), and group D was given compound raspberry seeds Powder (1.25g/kg) was administered into the stomach, and the drugs in groups C and D were dissolved to 2ml with normal saline, and the drugs were continuously administered for 7 days, with free drinking and eating;
步骤2,动物模型的建立:B、C、D组大鼠第7天灌胃结束后1h进行X射线全身一次性照射,总剂量为8Gy,剂量率为400cGy/min,源皮距100cm,建立急性放射性损伤大鼠模型;Step 2, establishment of animal model: B, C, and D rats were irradiated with X-ray whole body 1 hour after gavage on the 7th day, the total dose was 8Gy, the dose rate was 400cGy/min, and the source-to-skin distance was 100cm. Rat model of acute radiation injury;
步骤3,血样采集:辐射后禁食,24h后10%水合氯醛麻醉,腹主动脉取血5ml,加入到肝素钠抗凝管中,混匀,35ul全血分离淋巴细胞用于DNA损伤分析,1ml全血用作GSH-PX活力测定,其余全血离心后获取血浆置于-20℃冰箱保存待用;Step 3, blood sample collection: fasting after radiation, anesthetized with 10% chloral hydrate after 24 hours, take 5ml of blood from abdominal aorta, add it to heparin sodium anticoagulant tube, mix well, separate lymphocytes from 35ul whole blood for DNA damage analysis , 1ml of whole blood was used for GSH-PX activity determination, and the remaining whole blood was centrifuged to obtain plasma and stored in a -20°C refrigerator for later use;
步骤4,SOD、GSH-PX指标的测定:血清SOD活力采用WST-1法测定,酶标仪波长为450nm;全血GSH-PX酶活力采用比色法波长412nm测定;Step 4, determination of SOD and GSH-PX indexes: serum SOD activity is measured by WST-1 method, and the wavelength of microplate reader is 450nm; whole blood GSH-PX enzyme activity is measured by colorimetric method with wavelength of 412nm;
步骤5,DNA损伤的检测和分析:正常的淋巴细胞的细胞核应为大、圆、亮,根据细胞核不同程度的损伤经荧光染色后可出现“彗星”图像,“彗星”图像包括头部和尾部,根据两者的比例大小分为0、I、II、III、IV五个等级。0级无尾部,只是一个明亮的圆核,表明DNA无损伤。当DNA断裂损伤的程度由轻到重,则彗星尾部逐渐变长、变大,头部逐渐变小且荧光强度逐渐变弱。每个样本计数100个细胞,计算AU值后进行统计学分析,得到DNA损伤的总体水平;Step 5, detection and analysis of DNA damage: the nuclei of normal lymphocytes should be large, round, and bright. According to the different degrees of damage to the nuclei, a "comet" image can appear after fluorescent staining. The "comet" image includes the head and tail According to the ratio of the two, it is divided into five grades: 0, I, II, III, and IV. Grade 0 has no tail, just a bright round nucleus, indicating no damage to the DNA. When the degree of DNA breakage and damage ranges from mild to severe, the tail of the comet gradually becomes longer and larger, the head becomes smaller and the fluorescence intensity gradually becomes weaker. Count 100 cells for each sample, calculate the AU value and perform statistical analysis to obtain the overall level of DNA damage;
步骤6,统计学处理:采用SPSS 21.0统计软件进行统计学分析,数据以均数±标准差表示,组间比较采用单因素方差分析。Step 6, statistical processing: SPSS 21.0 statistical software was used for statistical analysis, and the data were expressed as mean ± standard deviation One-way analysis of variance was used for comparison between groups.
实验结果:Experimental results:
1.大鼠纳入实验的情况:B组1只大鼠在辐射后24h内死亡,腹部解剖后发现肠腔扩张、胀气、黏膜充血,考虑死亡原因为放疗并发症放射性肠炎。1. Rats included in the experiment: 1 rat in group B died within 24 hours after radiation. After abdominal dissection, it was found that the intestinal cavity was dilated, flatulent, and mucous membrane hyperemia. The cause of death was considered to be radiation enteritis, a complication of radiotherapy.
2.血浆SOD和全血GSH-PX活力值的比较详见表1:由表1可知与空白对照组比较,单纯照射组SOD活力大幅降低,有显著统计学意义(P<0.01),GSH-PX活力降低,有统计学意义(P<0.05);与单纯照射组比较,维生素联合应用组和复方树莓籽粉组SOD活力皆有升高,有统计学意义(P<0.05),GSH-PX活力增高,有统计学意义(P<0.05)。2. The comparison of plasma SOD and whole blood GSH-PX activity values is shown in Table 1. From Table 1, it can be seen that compared with the blank control group, the SOD activity in the simple irradiation group was significantly reduced (P<0.01), and the GSH-PX activity was statistically significant (P<0.01). PX activity decreased, with statistical significance (P<0.05); compared with simple irradiation group, SOD activity of vitamin combination group and compound raspberry seed powder group both increased, with statistical significance (P<0.05), GSH- The activity of PX increased, which was statistically significant (P<0.05).
表1各组大鼠SOD、GSH-PX活力比较 Table 1 Comparison of SOD and GSH-PX activity of rats in each group
注:与空白对照组比较,*P<0.01;与空白对照组比较,#P<0.05;与单纯照射组比较,&P<0.05Note: Compared with blank control group, *P<0.01; compared with blank control group, #P<0.05; compared with simple irradiation group, &P<0.05
淋巴细胞DNA损伤情况的分析如图1、图2所示。由图1可知,与空白对照组相比,单纯照射组淋巴细胞DNA损伤较为严重,有统计学意义(*P<0.05);与单纯对照组相比,维生素联合应用组和复方树莓籽粉组淋巴细胞DNA损伤较轻,有统计学意义(#P<0.05)。由图2可知,于空白对照组(图2A)相比,单纯照射组淋巴细胞DNA严重损伤,彗星尾部延长(图2B),维生素联合应用组(图2C)和复方树莓籽粉组(图2D)淋巴细胞DNA损伤较轻。The analysis of DNA damage in lymphocytes is shown in Figure 1 and Figure 2. It can be seen from Figure 1 that compared with the blank control group, the DNA damage of lymphocytes in the simple irradiation group was more serious, which was statistically significant (*P<0.05); compared with the simple control group, the combination of vitamins and compound raspberry seed powder The DNA damage of lymphocytes in the group was less severe, which was statistically significant (#P<0.05). It can be seen from Figure 2 that compared with the blank control group (Figure 2A), the DNA of lymphocytes in the simple irradiation group was severely damaged, and the tail of the comet was extended (Figure 2B), and the combination of vitamins (Figure 2C) and the compound raspberry seed powder group (Figure 2B) 2D) DNA damage in lymphocytes is mild.
实验证明本组方具有抗氧化功能,提升SOD、GSH-PX等活力。总的来说,本组方具有抗氧化、抗辐射、抗肿瘤的效果。造血系统是对辐射最敏感的系统之一,表现在外周血中即白细胞、红细胞、血小板数目降低。实验结果显示,预防性使用复方树莓籽粉能有效改善辐射对造血系统的损伤。本实验用彗星实验来评估淋巴细胞DNA的损伤程度。无论是通过统计学计算还是显微镜下肉眼所见,都可明显观察到维生素和复方树莓籽粉极好的保护了放射对淋巴细胞DNA的损伤作用。Experiments have proved that this formula has anti-oxidation function and can enhance the vitality of SOD and GSH-PX. In general, this formula has the effects of anti-oxidation, anti-radiation and anti-tumor. The hematopoietic system is one of the systems most sensitive to radiation, which is manifested in the decrease in the number of white blood cells, red blood cells, and platelets in peripheral blood. The experimental results show that preventive use of compound raspberry seed powder can effectively improve the damage of radiation to the hematopoietic system. In this experiment, comet assay was used to evaluate the degree of DNA damage in lymphocytes. Whether it is through statistical calculation or naked eye observation under a microscope, it can be clearly observed that vitamins and compound raspberry seed powder are excellent in protecting the damage effect of radiation on lymphocyte DNA.
以上所述仅为本发明的较佳实施例而已,并非用于限定本发明的保护范围。凡在本发明的精神和原则之内所作的任何修改、等同替换、改进等,均包含在本发明的保护范围内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present invention are included in the protection scope of the present invention.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611247287.3A CN106620018A (en) | 2016-12-29 | 2016-12-29 | Health-care product with anti-radiation effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611247287.3A CN106620018A (en) | 2016-12-29 | 2016-12-29 | Health-care product with anti-radiation effect and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106620018A true CN106620018A (en) | 2017-05-10 |
Family
ID=58836435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611247287.3A Pending CN106620018A (en) | 2016-12-29 | 2016-12-29 | Health-care product with anti-radiation effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620018A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107853570A (en) * | 2017-12-09 | 2018-03-30 | 党亮才 | A kind of anti-aging medicine congee of radioresistance and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002047656A1 (en) * | 2000-12-15 | 2002-06-20 | Kabushiki Kaisha Yakult Honsha | Compositions for retarding skin aging |
| CN101507460A (en) * | 2009-03-25 | 2009-08-19 | 肖社生 | Sanghong health protection tea |
| CN103211269A (en) * | 2013-05-20 | 2013-07-24 | 武汉药谷科技开发有限公司 | Distillate medicinal water for preventing and resisting electromagnetic radiation |
-
2016
- 2016-12-29 CN CN201611247287.3A patent/CN106620018A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002047656A1 (en) * | 2000-12-15 | 2002-06-20 | Kabushiki Kaisha Yakult Honsha | Compositions for retarding skin aging |
| CN101507460A (en) * | 2009-03-25 | 2009-08-19 | 肖社生 | Sanghong health protection tea |
| CN103211269A (en) * | 2013-05-20 | 2013-07-24 | 武汉药谷科技开发有限公司 | Distillate medicinal water for preventing and resisting electromagnetic radiation |
Non-Patent Citations (2)
| Title |
|---|
| 张炳文等主编: "《健康食品资源营养与功能评价》", 30 April 2007, 中国轻工业出版社 * |
| 王沛主编: "《执业药师资格考试学习指南 药学专业知识 2》", 31 January 2012, 金盾出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107853570A (en) * | 2017-12-09 | 2018-03-30 | 党亮才 | A kind of anti-aging medicine congee of radioresistance and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Protective effect of polysaccharides from Celluclast-assisted extract of Hizikia fusiforme against hydrogen peroxide-induced oxidative stress in vitro in Vero cells and in vivo in zebrafish | |
| Braun | Herbs & natural supplements | |
| KR100605292B1 (en) | Novel Ogapi and Ogapi Fruits, Ogapi Polysaccharides, Methods for Making the Same, and Anticancer Compositions Comprising the Same as Active Ingredients | |
| Wu et al. | Effects of hot-water extract of Toona sinensis on immune response and resistance to Aeromonas hydrophila in Oreochromis mossambicus | |
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| EP1466608B1 (en) | Herbal composition comprising Angelica gigantis, Cnidium officinale and Paeonia japonica | |
| Kim et al. | Immunomodulatory Effects of Kuseonwangdogo‐Based Mixed Herbal Formula Extracts on a Cyclophosphamide‐Induced Immunosuppression Mouse Model | |
| CN105194083A (en) | Medicine composition for enhancing immunity and resisting radiation and preparation method thereof | |
| CN103349711A (en) | Anti-aging combination with resveratrol and preparation method thereof | |
| CN101554362A (en) | Composition of natural product and preparation thereof | |
| Taiwo et al. | Haematological properties of aqueous extracts of Phyllantus amarus (Schum and Thonn.) and Xylopia aethiopica (Dunal) A. Rich in albino rats | |
| WO2012167656A1 (en) | Anti-radiation spriulina polysaccharide organic bio-active iodine and application thereof | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN106620018A (en) | Health-care product with anti-radiation effect and preparation method thereof | |
| Sidhu et al. | Silybum marianum: a plant of high medicinal importance—a review | |
| Foo et al. | Kenaf seed oil from supercritical carbon dioxide fluid extraction inhibits the proliferation of WEHI-3B leukemia cells in vivo | |
| Amer et al. | Effects of Rosemary and husk on hemogram and some biochemical parameters during treatment of ulcerative colitis in rats | |
| CN101463079A (en) | Calf chondroprotein, preparation and use thereof | |
| CN110559306B (en) | Application of rosin in the preparation of medicine for treating or preventing radiation damage | |
| Bhardwaj et al. | Development of cucurbocitrin based nutraceutical formulation: A potential adjuvant herbal therapy in the management of hypertension | |
| US20130202637A1 (en) | Dietary Supplements Including Ellagitannins and Ellagic Acid | |
| Singha et al. | RESEARCH DEVELOPMENTS IN IMMUNOMODULATORY AND ANTIOXIDANT ACTIVITIES OF SHILAJATU. | |
| Bazari Moghaddam et al. | Effects of nanoparticles of dried Aloe vera extract on some of the hematological parameters, liver enzymes and immune responses in Siberian sturgeon (Acipenser baerii) | |
| Hemdan | Inhibition of the Growth of Tumors Induced Ehrlich Ascites by Pre-Treatment with Pomegranate and Beetroot Juice in Mice | |
| Zbyňovská et al. | Oral and intramuscular application of cyanogenic glycoside amygdalin did not induce changes in haematological profile of male rabbits. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |